

# ANIMATED BANNERS

Preventing against severe COVID-19 outcomes

FRAME 1

[ **spikevax™**  
SARS-CoV-2 JN.1  
COVID-19 mRNA Vaccine  
by **moderna**]

[Abbreviated Product Information]

[ API ]

FRAME 2

As COVID-19  
continues  
to evolve,<sup>1</sup>

[Abbreviated Product Information]

[ API ]

FRAME 3

Consider  
updated  
[Spikevax]  
against [JN.1]  
variant

[Abbreviated Product Information]

[ API ]

FRAME 4

[Helping to/Help]  
protect patients  
(aged ≥65 years)  
against COVID-19  
infection<sup>2</sup>

[Learn more]

[Abbreviated Product Information]

[ API ]

FRAME 5

[Abbreviated Product Information]

[ API ]

[Please see Abbreviated Product Information and full Summary of Product Characteristics at Spikevax.eu].

**REFERENCES:** 1. World Health Organization. Statement on the antigen composition of COVID-19 vaccines. Updated April 26, 2024. [Accessed August 5, 2024.] <https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines> 2. [Spikevax Summary of Product Characteristics. Moderna; 2024.]

[©2024 Moderna GL-COV-2400059 08/2024]